Press Releases

Investor Alerts

Mar 25, 2021

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

- Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022
Mar 10, 2021

Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference
Mar 1, 2021

Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing
Mar 1, 2021

Satsuma Pharmaceuticals Announces Updated STS101 Development Plan

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-
Nov 24, 2020

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

Show per page